{"classes":[{"categories":[{"measurements":[{"comment":"Data not available due to high censoring.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Data not available due to high censoring.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg\\] IV) or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With Pembrolizumab (TRT B)"}],"paramType":"MEDIAN","populationDescription":"ITT Pembrolizumab: Participants included in the ITT population who were stratified with the intent to receive pembrolizumab in the event of the control-arm assignment. Participants censored: TRT A: 103; TRT B: 62","reportingStatus":"POSTED","timeFrame":"Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months","title":"PFS2 (With Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Months"}